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Abstract
Background: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with
metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety
outcomes in patients treated with regorafenib in a real-life setting.
Methods: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival,
safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory
to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated
using univariate and multivariate Cox proportional hazards regression models.
Results: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up
was 16.5 months. Median survival was 5.6 months. The 12-month survival rate was 22 %. Survival was
independently and unfavourably affected by the following variables: poor performance status, short time from
initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence
of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and
high risk of death, with a median survival of 9.2, 5.2, and 2.5 months, respectively. Five-hundred-twenty-four
patients (80 %) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin
reaction, diarrhea, anorexia, arterial hypertension, and mucositis.
Conclusion: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our
prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib.
Trial registration: Clinicaltrials.gov NCT02310477.
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Background
Regorafenib is an oral multikinase agent that inhibits an-
giogenic and stromal receptor tyrosine kinases such as
VEGFR1/3, PDGFR-b, FGFR-1, and TIE-2. Together
with inhibition of oncogenic receptor tyrosine kinases c-
KIT, and RET, regorafenib also blocks the activity of sig-
naling kinases such as RAF1 and B-RAF [1].
Two phase III trials demonstrated a significant overall
survival (OS) benefit for regorafenib over placebo in pa-
tients with metastatic colorectal cancer (mCRC) who
progressed on standard therapies [2, 3]. As a result, re-
gorafenib was granted marketing authorization in many
countries for mCRC at a dose of 160 mg/day for the first
3 weeks of each 4-week cycle.
Because patient selection and real-life prescribing con-
ditions may differ from those of randomized clinical tri-
als, we evaluated the efficacy, safety, and potential
predictors of outcome in patients treated with regorafe-
nib in this setting. Once approved in France for the
treatment of mCRC, but before full reimbursement was
possible, the French authorities made regorafenib avail-
able through a Temporary Use Authorization (Autorisa-
tion Temporaire d’Utilisation or ATU) program. This is
an exceptional procedure approved by the French Na-
tional Agency for Medicines and Health Products Safety
(ANSM) intended to provide early access to new medi-
cines, especially for unmet needs. Prescribing conditions,
based on the ATU label, are less stringent than selection
criteria in clinical trials. The ATU data contributes to
better understanding of the medicinal product and a re-
liable evaluation of its benefit/risk ratio in the real-life
setting.
The REgorafeniB in mEtastatic Colorectal cancer: a
French Compassionate progrAm (REBECCA) is a cohort
study nested within the ATU designed to evaluate the ef-
ficacy and safety of regorafenib in real-life clinical prac-
tice for mCRC patients who have been previously
treated with or are not considered candidates for stand-
ard therapies.
Methods
This study was performed according to the Declaration of
Helsinki. Written consent was not required from patients,
according to French laws governing noninterventional
studies. However, patients alive at the time of the study re-
ceived full information by the investigators, regarding the
research and the anonymous data collection. If a patient
refused participation, the registration was not performed.
Ethic approvals were obtained by submission of the study
to the “Consultative Committee for Data processing in Re-
search in the Health field” (CCTIRS, file 14–042, approval
date: January 15th, 2014), and to “National Committee of
data processing for data protection” (CNIL, file 914071,
approval date: May 22nd, 2014). The study is registered in
clinicaltrials.gov (NCT02310477). REBECCA was con-
ducted in France at 136 institutions that completed an
updated case report form, including 42 university/compre-
hensive cancer hospitals, 45 general hospitals, and 39 pri-
vate practice clinics. Because some physicians or patients
did not agree to participate to that study, the study popu-
lation was a subset of the 1178 adults with histologically
proven mCRC satisfying the criteria for regorafenib treat-
ment validated by the ANSM in the ATU (Fig. 1). Data
were collected from 690 patients and the 654 who re-
ceived at least one regorafenib dose comprised the Full
Analysis Set (FAS). Case report forms from at least 60 %
of patients were randomly monitored for accuracy. Pa-
tients were treated with regorafenib from October 2012 to
Fig. 1 REBECCA flow chart
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January 2014. The median follow-up was 16.5 months
(range: 1 day–21.9 months). Data cutoff was December
16, 2014. Baseline demographic and clinical variables were
retrospectively collected, whereas survival data and post
progression treatments were prospectively collected. Base-
line demographic and clinical variables included: age, sex,
BMI, ECOG PS, institution type, number of treated pa-
tients per center, primary tumour location, time from ini-
tial diagnosis of metastases and start of regorafenib,
synchronous/metachronous metastases, number of meta-
static sites, sites of metastases, KRAS mutational status,
previous bevacizumab therapy, time from last bevacizu-
mab, and initial regorafenib dose. Treatment compliance,
dose-intensity, adverse events (AEs), pre- and post-
regorafenib treatments, and potential prognostic factors
for OS were also evaluated. Severity of AEs was graded
using National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0.
Statistics
Descriptive statistics were used to summarize data.
Median follow-up was calculated by the inverse Kaplan-
Meier method. All time-to-event variables were calcu-
lated from the date of first regorafenib administration.
OS was calculated to the date of death; patients alive at
the time of analysis were censored at the last observa-
tion. Progression-free survival (PFS) was defined as the
time to first progression or death, whichever came first;
non-progressing patients alive at the time of analysis
were censored at last follow-up. Hazard ratios (HR) were
estimated from the semi-parametric Cox proportional
hazards model. Treatment effects were evaluated by
univariate and multivariate Cox proportional hazards re-
gression models for OS.
For prognostic scores, we first did a univariate analysis
of demographic and clinical variables and retained those
significant at the 0.10 level in the multivariate model.
Next, we combined significant prognostic factors from
the multivariate model to define a prognostic score for
patients with similar risks of death by rounding regres-
sion coefficients to the nearest integer to obtain relative
weights of the variables and summing them to obtain a
total score. This score ranged from 0 to 10 and was then
reduced to three prognostic groups by combining adja-
cent non-significant categories (Wald test) from hier-
archically defined dummy indicator variables to obtain
three categories of patients with significantly different
risks of death. Other potential prognostic variables were
then added to this reduced model and tested for signifi-
cance using the likelihood ratio statistic.
Exploratory post hoc analyses assessed the OS
prognostic score in a subgroup of FAS patients having
characteristics similar to patients in CORRECT [2], in-
cluding ECOG PS 0–1, 160 mg initial regorafenib dose,
and previous exposure to bevacizumab (FAS-CORRECT
population, n = 440). We also evaluated the impact of
toxicity type on OS, recalibrated from 1 month after the
start of regorafenib.
Results
Baseline characteristics are listed in Table 1. Thirty-one
percent and 48 % of patients had 1 and 2 or more
metastatic sites, respectively, mostly to liver and lung.
Thirty-five percent of patients had at least 3 prior lines
of treatment for metastatic disease and 15 % had 5 lines
or more. Almost all received prior oxaliplatin and irino-
tecan (99 %), 92 % had prior bevacizumab, and 283/291
(97 %) of patients with KRAS wild-type tumours had
previously received anti-EGFR therapy. The median time
since last bevacizumab was 4.4 months. Baseline patient
and disease characteristics were similar to those of the
overall ATU population (data not shown). Patients were
similarly distributed among university/comprehensive
cancer hospitals, general hospitals, and private clinics. A
majority of centres (55 %) included 7 patients or more.
Median regorafenib treatment duration was 2.2 months
(range, 0.1–20.5) and 13 patients were still on therapy at
data cut-off. An initial 160 mg daily dose was given to
80 % of patients (Table 1). The actual mean dose-
intensity during the first month of regorafenib was
751.2 mg per week (SD+/−142.2), i.e. 89 % of the ex-
pected figure. Fifty percent of patients had a treatment
modification (dose reduction or interruption). A total of
204 patients (31 %) either temporarily or permanently
stopped regorafenib before progression, mainly for tox-
icity (Table 2) and 43 % had dose reductions mainly for
toxicity or general health status deterioration. Median
time to first treatment modification was 0.7 months
(range, 0.03–6.01). Of patients starting cycles 3 and 4, 50
and 39 % received the full regorafenib dose, respectively.
Median OS was 5.6 months (interquartile range [IQR],
2.4–11.4). Twelve-month OS rate was 22 %. OS was
worse in patients with low BMI, ECOG PS >0, and in
patients managed in university/comprehensive cancer
centers or general hospitals. A short time since the diag-
nosis of metastases, the presence of synchronous or liver
metastases, a high number of metastatic sites, a low ini-
tial regorafenib dose, a short time since prior bevacizu-
mab, and KRAS mutations were also associated with a
shorter OS. Dose-intensity at 1 or 2 months after start-
ing regorafenib did not impact OS. Multivariate analysis
showed OS was independently affected by ECOG PS,
time since initial diagnosis, initial daily dose, number of
metastatic sites, liver metastases, and KRAS mutation
(Table 3).
The low-risk group (regorafenib high OS benefit) with
a maximum prognostic score of 3, represented 34 % of
patients having a median OS of 9.2 months (Table 4,
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Fig. 2). The moderate-risk group score was 4 or 5 and
represented 42 % of patients with a median OS of
5.2 months. The high-risk group (low OS benefit) had a
score of 6 or more and represented 24 % of patients hav-
ing a median OS of 2.5 months.
A post hoc exploratory analysis of the FAS-CORRECT
population showed a median OS of 6.3 months and a
12-month OS rate of 23 %. From the variables found
significantly related to OS after univariate and multivari-
ate analyses (data not shown), the OS prognostic score
of the FAS-CORRECT population was similar to that of
the FAS (Table 4). However, fewer FAS-CORRECT pa-
tients (11 vs 24 %) were classified as low OS benefit
from regorafenib and more were classified as high OS
benefit (42 vs 34 %).
The median time to first tumour assessment from
treatment initiation was 2.6 months (range, 0.3–6.3).
Median PFS was 2.7 months (IQR, 1.6–4.6) and 12-
month PFS rate was 7 %.
Safety
Overall 524/654 (80 %) of patients had at least one AE
the investigator considered regorafenib-related (Table 5).
Worst AE grade was not available for 12 patients. Rates
of worst-grade AEs in 512 patients were: grade 1 (n = 53,
10 %), grade 2 (n = 171, 33 %), grade 3 (n = 231, 45 %),
grade 4 (n = 55, 11 %) and grade 5 (n = 2, <1 %). Two
deaths (one fronto-parietal lobar cerebral hematoma and
one bowel perforation) were suspected to be related to
regorafenib. Most frequently (>10 %) reported
regorafenib-related AEs were fatigue, hand-foot skin re-
action (HFSR), diarrhea, anorexia, arterial hypertension,
and mucositis (Table 5). Most common grade 3–4
regorafenib-related AEs were fatigue and HFSR. Occur-
rence of HFSR during the first month of treatment was
associated with a statistically significantly better OS (HR,
0.61 [95 % CI, 0.50–0.74]; p < 0.0001). Patients (n = 197)
who presented with HFSR during the first month of
treatment had apparently better median survival
(7.7 months vs 4.1 months), and 6-months survival rate
(61 vs 39 %), that patients who did not (n = 392). This
was not observed for other toxicities.
Table 1 Selected baseline patient and disease characteristics
FAS population
Age (years): median (range) 64 (25–91)
Age (years): n (%)
< 65 343 (52.4)
≥ 65 311 (47.6)
BMI (Kg/m2) 24 (14.1–49.1)






Site of Primary tumour: n (%)
Colon 445 (69.9)
Rectum 186 (29.9)
Colon and rectum 5 (0.2)
Missing 18




Delay from initial diagnosis of metastases (months):
median (range)
31 (0.8–156.5)
Delay from initial diagnosis of metastases (months): n (%)
< 18 134 (20.6)
≥ 18 518 (79.4)
Missing 2










Table 2 Treatment modifications
FAS population
Dose interruptionsa: n (%) 204 (31.2)
Reasons: n (%)
Patient willingness 8 (3.9)
General health deterioration 29 (14.2)
Adverse event (treatment-related or not) 173 (84.8)
Other 9 (4.4)
Dose reduction: n (%) 278 (42.5)
Reasons: n (%)
Patient willingness 6 (2.2)
General health deterioration 66 (23.7)
Disease progression 2 (0.7)
Adverse event (treatment-related or not) 226 (81.3)
Other 20 (7.2)
Any kind of dose modification: n (%) 329 (50.3)
aPermanent or temporary interruption
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A total of 223 patients (34 %) received at least one post-
regorafenib therapy, including 89/223 patients who re-
ceived more than one line of post-regorafenib treatment.
108/223, 100/223, and 15/223 patients were treated with
chemotherapy only, with chemotherapy plus targeted
therapies, and with targeted therapies only, respectively.
Overall, a rechallenge with anti-EGFR agents was ob-
served in 52 patients with presumably KRAS wild-type tu-
mours. The median OS (from date of progression on
regorafenib to death) in 152 patients who received post-
progression treatment was 7.9 months (range, 6.1–9.0),
and was 3.4 months (range, 3.1–3.8) in 431 patients who
did not receive any post-progression therapy.
Discussion
The CORRECT trial showed that regorafenib signifi-
cantly improves OS (HR [95 % CI]: 0.77 [0.64–0.94]) and
PFS (0.49 [0.42–0.58]) versus placebo in patients with
mCRC that progressed after standard therapies [2].
These results were confirmed, although with a greater
survival benefit for regorafenib, by a recently published
trial of Asian patients, a significant proportion of whom
had not received a prior targeted agent [3]. In these tri-
als, a vast majority of regorafenib-treated patients had at
least one AE, most commonly HFSR, fatigue, diarrhea,
hypertension, anorexia, oral mucositis, hoarseness, liver
enzymes, and bilirubin changes. One third to half of
these AEs were classified as grade >2, with fatigue and
HFSR (no grade 4) being the most frequent [2, 3].
Because patients and prescribing conditions in real-life
may differ from phase III trials, data on efficacy, safety,
and on potential predictors of outcomes in patients
treated with regorafenib in this setting are important for
future clinical use and to potentially identify patients
who may benefit most from treatment.
Indeed, REBECCA should be interpreted carefully be-
cause its limitations due to its retrospective design and
its exploratory subgroup analyses. However, it provides
insights into real-life clinical practice in a large cohort of
654 carefully monitored patients who represent the par-
ent ATU population.
As prescribing conditions in the ATU are less strin-
gent than in clinical trials, it is not surprising that some
patient characteristics in REBECCA differed from those
in CORRECT [2]. For example, in REBECCA 11 % of
patients had a baseline ECOG PS >1 and 20 % initially
received <160 mg/day of regorafenib, whereas in COR-
RECT all patients were ECOG PS0–1 at baseline and all
started at 160 mg/day. Median OS in REBECCA was
5.6 months and 22 % of patients were alive 12 months
after starting regorafenib. Although consistent with
CORRECT [2] (median OS 6.4 months, 12-month sur-
vival 24 %), the slightly lower median OS may be related
to different patient characteristics in the real-life setting.
Limiting our analysis to REBECCA patients having simi-
lar baseline characteristics as patients in CORRECT
(FAS-CORRECT), showed results closer to the clinical
trial (median OS 6.3 months; 12-month OS rate 22.8 %).
Median PFS in REBECCA (2.9 months) appeared better
than in CORRECT (1.9 months), but this should be
interpreted with caution because the median time to
first tumor assessment was longer in real-life (13 weeks)
than in the prospective trial (8 weeks).
Table 3 OS multivariate analysis on FAS and FAS CORRECT
populations





ECOG Performance Status <0.001
0 1 0
1 1.54 (1.26–1.88) +2
≥ 2 3.43 (2.50–4.70) +4
Time since initial diagnosis <0.001
≥ 18 months 1 0
< 18 months 1.72 (1.40–2.13) +2
Initial daily dose of regorafenib 0.042
160 1 0
< 160 1.26 (1.01–1.57) +1
Number of metastatic sites 0.020
< 3 1 0
3+ 1.29 (1.04–1.60) +1
Liver metastases <0.001
No 1 0
Yes 1.61 (1.29–2.01) +2
KRAS 0.016
Wild-type 1 0
Mutated 1.25 (1.04–1.49) +1
FAS CORRECT Population
ECOG Performance Status 0.001
0 1 0
1 1.45 (1.16–1.81) +1
≥ 2
Time since initial diagnosis 0.001
≥ 18 months 1 0
< 18 months 1.55 (1.21–1.99) +1
Number of metastatic sites 0.013
< 3 1 0
3+ 1.38 (1.07–1.77) +1
Liver metastases <0.001
No 1 0
Yes 1.65 (1.28–2.13) +1
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No predictive factors for OS have been identified for
mCRC patients treated with regorafenib, although a sub-
group analysis from CONCUR suggests that prior
exposure to targeted therapies (bevacizumab and/or
anti-EGFR) may influence OS [3]. In CORRECT, no as-
sociation between KRAS, BRAF, and PIK3CA mutation
status and outcomes with regorafenib was identified [4].
Conversely, in our real-life study we identified several
variables independently associated with OS. High ECOG
PS, a shorter time from initial diagnosis of metastases,
an initial REG dose <160 mg, >3 metastatic sites, liver
metastases, and KRAS mutations, were independently
associated with poorer survival, suggesting that with
these easily-collected baseline variables, patients could
be classified into similar prognostic groups. More im-
portantly, we were able to identify patients having a
small probability of benefiting from regorafenib. This
predictive pattern was reproduced in the FAS-
CORRECT population that was clinically similar to
CORRECT, in which we identified patients (about 10 %
of the FAS population) with a particularly poor outcome
(median OS = 3.4 months).
The AEs reported in REBECCA are consistent with
previous studies of regorafenib in mCRC, with fatigue,
HFSR, hypertension, and diarrhea being the most fre-
quent. However, it appeared than the rate of treatment-
related AEs of any grade is lower in REBECCA (80 %),
than that in CORRECT and CONCUR (97 and 93 %, re-
spectively). This discrepancy may be related to the retro-
spective design of our study.
Additionally, we showed that the occurrence of HFSR
within the first month of treatment was related to a bet-
ter OS. Obviously, this finding needs to be confirmed, as
it was based on an unplanned exploratory analysis using
a landmark method restricted to patients who were alive
without progression at 1 month. Whether or not the oc-
currence of a cutaneous AE within the first month of re-
gorafenib treatment is predictive for outcome has to be
confirmed prospectively by a multivariate analysis of po-
tential predictive markers.
Table 4 OS prognostic score in the FAS and the FAS CORRECT populations
FAS Population n = 654 Median OS 6-month OS rate
Score equal to 0,1, 2, or 3 (high benefit from REG, n = 213) 1 9.2 67 %
Score equal to 4 or 5 (moderate benefit from REG, n = 256) 1.78 (1.45–2.18) 5.2 45 %
Score equal to 6+ (low benefit from REG, n = 147) 2.70 (2.13–3.42) 2.5 26 %
FAS-CORRECT Population n =440
Score equal to 0 or 1 (high benefit from REG, n = 185) 1 8.7 64 %
Score equal to 2 (moderate benefit from REG, n = 206) 1.67 (1.34–2.09) 5.5 46 %
Score equal to 3 (low benefit from REG, n = 48) 2.54 (1.79–3.60) 3.4 35 %
Relative weights of the variables found independently related to survival (see Table 3) were added to obtain a total score. This score ranged from 0 to 10, and
was then reduced to obtain three categories of patients with significantly different risks of death
Fig. 2 OS according to prognostic scores (FAS population)
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Forty-three percent of the patients had a dose reduction
for toxicity or general health status deterioration. Of pa-
tients starting the fourth cycle, only 39 % received regoraf-
enib at full dose. A similar proportion of dose reductions
were also found in CORRECT [2] and in CONSIGN, a
large (n = 2872) open-label phase IIIb study of patients
with mCRC presented at the 2015 World Congress on
Gastrointestinal Cancer [5]. Obviously, the question of re-
gorafenib dose is critical, as it is related to efficacy, safety,
compliance, regulatory issues, and medication costs. At
least one randomised trial comparing a lower dose of re-
gorafenib with a standard dose in patients with refractory
mCRC is underway (NCT02368886).
Finally, one-third of patients who were treated after
progression on regorafenib had a clinically better OS
which, as has been suggested, shows that despite un-
proven efficacy, there may be room for further treatment
in selected patients [6].
Conclusion
The survival and safety profiles of regorafenib in the
real-life setting are similar to those reported in prospect-
ive trials. We found that some variables may be associ-
ated with either better or worse OS and that our
prognostic model was able to categorize mCRC patients
into groups deriving a minimal and maximum benefit
from regorafenib. Whether our findings are of predictive,
and/or of prognostic value is not clear and warrants fur-
ther investigation.
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